Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Idelalisib is used in combination with another medication (rituximab) only after the disease has relapsed or is no longer responding to other CLL and SLL treatments.
At the American Society of Clinical Oncology (ASCO) Annual Meeting in 2022, we received the four-year follow-up data update on the ASCEND trial.
This trial compared acalabrutinib (acala) to the treating doctor’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia.
Dr. Jeff Sharman and colleagues presented this research at the American Society for Hematology annual meeting held December 2021 (ASH 2021).
Idelalisib (Zydelig) was once known as CAL-101 and was the most exciting new oral therapy in the CLL world, the shining morning star in the dawn of a new era of treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL).
During ASH 2020, Dr. Paolo Ghia discussed the ASCEND Study – Acalabrutinib vs. Idelalisib + Rituximab or Bendamustine + Rituximab in Relapsed or Refractory CLL. Dr. Ghia presented the final analyses of the ASCEND trial after nearly two years of follow-up. Acalabrutinib was the clear winner.
At the 2017 ASH Annual Meeting, Dr. Brian Koffman interviewed Dr. Jennifer Brown from Dana Farber Cancer Institute at Harvard University in Boston regarding the association between idelalisib and liver inflammation
By Tom Henry – CLL Patient and Pharmacist Idelalisib (eye-del-a-lis-ib), which is marketed under the tradename of Zydelig® in the United States and Canada, is a selective inhibitor of the lipid
There is little question that the approval of kinase inhibitor therapies such as ibrutinib have revolutionized the care of patients with CLL. Ibrutinib is active in many circumstances where many traditional
In heavily treated chronic lymphocytic leukemia patients who have poor prognoses and few options, the BTK degrader, NX-5948, was responsive.
One click to our most popular content.
